Imalux seeks to confirm OTC's (Optical coherence tomography) value in major EU bladder cancer trials:
This article was originally published in Clinica
Optical coherence tomography (OCT) manufacturer Imalux has begun a series of European bladder cancer trials to support its technology's value in identifying the earliest signs of the disease. One German study, which will involve over 25,000 patients, will also assess the technology's use in preventing tumour recurrence and progression. The Cleveland, Ohio firm's Niris OTC imaging system, which is already cleared for sale in the US and Europe, will be used in the studies. According to the company, the "application of the proven OCT technology is on the verge of becoming the sixth major imaging modality".